



Niger COVID-19 Emergency Response Project (P173846)

AFRICA WEST | Niger | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 4 | ARCHIVED on 18-Feb-2022 | ISR50102 |

Implementing Agencies: Ministry of Public Health, Population and Social Affairs, Republic of Niger

Key Dates

Key Project Dates

Bank Approval Date: 13-Apr-2020

Effectiveness Date: 08-Jul-2020

Planned Mid Term Review Date: 17-Oct-2022

Actual Mid-Term Review Date:

Original Closing Date: 30-Apr-2022

Revised Closing Date: 31-Dec-2024

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Niger

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Component 1: Emergency COVID-19 Response:(Cost \$37.55 M)

Component 2: Communication campaign, community engagement and Behavior change:(Cost \$3.00 M)

Component 3: Implementation Management and Monitoring and Evaluation:(Cost \$2.60 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Moderately Satisfactory
Overall Risk Rating	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

Overall, the project implementation progress is satisfactory. The project continues to maintain progress in activities' implementation and especially in acquisitions for COVID-19 response.

The COVID-19 Additional Financing project of US\$ 29.2 million was declared effective on December 17, 2021. The AF will support country efforts on vaccine deployment and acquisition and therefore accelerate progress on COVID-19 vaccination in Niger.

MPA Program Development Objective



The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

As of January 17, 2022, 87 MPA-projects had been approved with a total commitment of US\$4.2 billion. One operation (Guatemala) was canceled in mid-September 2021, at the request of the Government. Therefore, there are 86 MPA active operations. Fifty-eight (58) country projects or 67% of projects approved have reached 70-100% disbursement (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). Out of the 58 projects, 35 operations or 60% have disbursed over 90% of commitments. The projects are benefitting around 3.7 billion people or 50% of the global population. Of the 86 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 7 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-five (85) or 99% of projects approved are disbursing. **Total disbursements as of January 17, 2022, amounted to US\$3.30 billion or 78% of overall commitments.** Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. **Six parent projects have been restructured to include vaccine-related procurement.** Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Implementation continues to face challenges as several countries are still under different levels of lockdown or mobility restrictions, and counterparts and Bank teams are operating from home or partially from home. Also, countries are dealing with new waves of infections as the Omicron variant is spreading rapidly among populations. The variant which was first identified in South Africa and Botswana has been detected in more than 80 nations by mid-December. Many Bank teams continue to conduct implementation support missions virtually, which is challenging for both Bank teams and counterparts. This “virtual” world poses connectivity challenges as the internet is not reliable in many countries, especially IDA countries. Notwithstanding the challenges, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements attests to the strong implementation of the Bank’ response thanks to the commitment of counterparts supported by Bank country teams.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach (“Global COVID-19 MPA”) was approved by the Board on October 13, 2021. The AF-V is significantly expanding Bank support to client countries for COVID-19 vaccination, with the aim to support vaccination of 1 billion people globally. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG’s overall COVID-19 response.

As of January 17, 2022, the Bank has approved 83 operations to support vaccine procurement and rollout in 69 countries amounting to \$7.6 billion. The 83 AF-V operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 83 approved operations: (i) 45 are in Africa – 21 in AFE and 24 in AFW; (ii) 8 in East Asia; (iii) 9 in Europe and Central Asia; (iv) 6 in Latin America and the Caribbean; (v) 7 in Middle East and North Africa; and (vi) 8 in South Asia. Forty-three (43) projects are disbursing. Thirty new operations are under various stages of processing. **Total disbursements as of January 17, 2022, under these projects amount to US\$1.8 billion or 24% of overall commitments.** As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Seventy (70) loan/financing agreements have been signed. Also, sixty (60) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of lockdown or mobility restrictions and counterparts and Bank teams are operating from home. Countries are dealing with new waves of infections as the Omicron variant is spreading



rapidly among populations. The variant, which was first identified in South Africa and Botswana, has been detected in more than 80 nations by mid-December.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	High	Substantial	Substantial
Macroeconomic	High	Substantial	Substantial
Sector Strategies and Policies	Moderate	Moderate	Moderate
Technical Design of Project or Program	Substantial	Moderate	Moderate
Institutional Capacity for Implementation and Sustainability	Moderate	Substantial	Substantial
Fiduciary	High	Substantial	Substantial
Environment and Social	Substantial	Substantial	Substantial
Stakeholders	Moderate	Moderate	Moderate
Other	--	--	--
Overall	Substantial	Substantial	Substantial

Results

PDO Indicators by Objectives / Outcomes

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for p				
► Efficiency of a public health coordination mechanism for COVID-19 (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	Country has established its coordination mechanism for COVID-19 with daily reporting of different commissions			
► Suspected cases of COVID-19 cases reported and investigated based on national guidelines (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	99.91	99.81	100.00



Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	30-Apr-2022
Comments:	Numerator: Number of suspected cases of COVID-19 cases reported and investigated based on national guidelines Denominator: Number of of suspected cases of COVID-19 cases reported and investigated			
▶ Laboratories with trained staff and consumables for collecting COVID-19 samples and transporting to the National Public Health Laboratory (Centre de Recherche Médicale et Sanitaire, CERMES) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	17.00	17.00	4.00
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	Cumulative targeted laboratories equipped with COVID-19 diagnostic equipment			
▶ Targeted regions with pandemic preparedness and response plans per Ministry of Public Health Guidelines (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	100.00
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	Numerator: number of targeted regions with pandemic level response plan according to Ministry of Public Health guidelines. Denominator: number of targeted regions			
▶ Population vaccinated, which is included in the priority population targets defined in national plan (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	4.20	25.00
Date	12-Mar-2021	12-Mar-2021	14-Feb-2022	31-Dec-2024
□ Population vaccinated, which is included in the priority population targets defined in national plan - Female (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	1.50	10.00
Date	11-Jun-2021	11-Jun-2021	14-Feb-2022	31-Dec-2024

Intermediate Results Indicators by Components

Component 1: Emergency COVID-19 Response

▶ Personal protective equipment (PPE) kits delivered to health facilities (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
--	----------	-------------------	------------------	------------



Value	0.00	500,000.00	500,000.00	12,000.00
Date	24-Mar-2020	02-Jul-2021	14-Feb-2022	31-Dec-2024
Comments:	Cumulative number of PPE kits distributed to health facilities			
► Health staff trained in infection prevention per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	300.00	300.00	300.00
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	Cumulative number of staff receiving infection prevention control (IPC) or similar training via the project			
► Laboratories with trained staff and consumables for collecting COVID-19 samples and transporting to National Public Health laboratory (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	17.00	17.00	12.00
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
► Targeted healthcare facilities with clinical capacity for COVID-19 patients (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	56.00	56.00	12.00
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	Numerator: Total number of targeted healthcare facilities with capacity to treat COVID-19 patients Denominator: Total number of targeted health care facilities for COVID-19 patients			
► Doses of eligible COVID-19 vaccines delivered in-country (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	2,000,000.00
Date	11-Jun-2021	11-Jun-2021	14-Feb-2022	31-Dec-2024
► People trained on the installation, monitoring and maintenance of the cold chain equipment (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	200.00
Date	12-Mar-2021	12-Mar-2021	14-Feb-2022	31-Dec-2024
<input type="checkbox"/> People trained on the installation, monitoring and maintenance of the cold chain equipment-Female (Number, Custom Breakdown)				



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	60.00
Date	11-Jun-2021	11-Jun-2021	14-Feb-2022	31-Dec-2024
► Expansion of functioning cold chain equipment and stored vaccines (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	124.00
Date	12-Mar-2021	12-Mar-2021	14-Feb-2022	31-Dec-2024
□ Expansion of functioning cold chain equipment and stored vaccines in urban, nomadic and desert areas- nomadic and desert areas (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	60.00
Date	04-Jun-2021	04-Jun-2021	14-Feb-2022	31-Dec-2024

Component 2: Communication campaign, community engagement and Behavior change

► Country has developed a communication and risk communication plan including community engagement strategies (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	Existence of a communication and risk communication plan			

► Radio Stations broadcast COVID-19 risk communication message (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	12.00	90.00
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	Cumulative number of COVID-19 sensitization campaigns conducted as per contextualized their risk communication and community engagement strategies			

► Gender sensitive educational materials on COVID-19 vaccines distributed (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes



Date	07-May-2021	07-May-2021	14-Feb-2022	31-Dec-2024
▶ Grievances received and addressed within the defined timeframe (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	2.00	90.00
Date	11-Jun-2021	11-Jun-2021	14-Feb-2022	31-Dec-2024

Component 3: Implementation Management and Monitoring and Evaluation				
▶ M&E system established and implemented to monitor project progress (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	24-Mar-2020	12-Feb-2021	14-Feb-2022	31-Dec-2024
Comments:	M&E system has been established and implemented to monitor project progress			

Performance-Based Conditions

Data on Financial Performance

Disbursements (by loan)


Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173846	IDA-66200	Effective	USD	6.98	6.98	0.00	2.55	4.78	35%
P173846	IDA-69570	Effective	USD	14.00	14.00	0.00	0.00	12.97	0%
P173846	IDA-D6180	Effective	USD	6.98	6.98	0.00	7.42	0.00	100%
P173846	IDA-D8700	Effective	USD	14.00	14.00	0.00	0.00	13.58	0%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173846	IDA-66200	Effective	13-Apr-2020	08-May-2020	08-Jul-2020	30-Apr-2022	31-Dec-2024
P173846	IDA-69570	Effective	25-Jun-2021	27-Aug-2021	17-Dec-2021	31-Dec-2024	31-Dec-2024
P173846	IDA-D6180	Effective	13-Apr-2020	08-May-2020	08-Jul-2020	30-Apr-2022	31-Dec-2024
P173846	IDA-D8700	Effective	25-Jun-2021	27-Aug-2021	17-Dec-2021	31-Dec-2024	31-Dec-2024



Cumulative Disbursements



PBC Disbursement

PBC ID	PBC Type	Description	Coc	PBC Amount	Achievement Status	Disbursed amount in Coc	Disbursement % for PBC
--------	----------	-------------	-----	------------	--------------------	-------------------------	------------------------

Restructuring History

There has been no restructuring to date.

Related Project(s)

P176345-Niger COVID-19 Emergency Response Project - Additional Financing